CBS-0550 is a drug developed by
Taisho Pharmaceutical, which acts as a potent and selective
cannabinoidCB2receptoragonist, with 1400x selectivity for CB2 over the related
CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce
analgesic and anti-
hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]
^Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, et al. (February 2008). "Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action". Bioorganic & Medicinal Chemistry. 16 (3): 1111–24.
doi:
10.1016/j.bmc.2007.10.087.
PMID18006322.
^Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, et al. (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–304.
doi:
10.1016/j.bmcl.2007.09.004.
PMID17884496.